Scopus BioPharma Inc. financial data

Industry
Pharmaceutical Preparations
Location
420 Lexington Avenue, Suite 300, New York, NY
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2023 - Aug 11, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity 122 %
Return On Assets -1.2K % -248%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.1M shares +99.5%
Common Stock, Shares, Outstanding 39.6M shares +87.7%
Common Stock, Value, Issued 39.8K USD +88.6%
Weighted Average Number of Shares Outstanding, Basic 39.7M shares +88.4%
Weighted Average Number of Shares Outstanding, Diluted 39.7M shares +88.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 5.27M USD +327%
General and Administrative Expense 4.08M USD -74.6%
Net Income (Loss) Attributable to Parent -8.7M USD +45.3%
Earnings Per Share, Basic -0.32 USD/shares +57.3%
Earnings Per Share, Diluted -0.32 USD/shares +57.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 362K USD -68.7%
Assets, Current 496K USD -70.3%
Property, Plant and Equipment, Net 1.7K USD -39.5%
Assets 498K USD -70.3%
Liabilities, Current 11M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 30.2K USD
Retained Earnings (Accumulated Deficit) -58.1M USD -17.6%
Stockholders' Equity Attributable to Parent -9.45M USD -156%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -10.5M USD
Liabilities and Equity 498K USD -70.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -760K USD +80.9%
Net Cash Provided by (Used in) Financing Activities 2.02M USD
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 39.8M shares +88.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.28M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 362K USD -68.7%
Depreciation 334 USD -42.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -8.65M USD +45.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 48.6M USD +6.31%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 318K USD -35%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%